LeonaBio, Inc.
LONAAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 19, 2026 | Mizuho Securities | Graig Suvannavejh | $15.00(+84%) | $8.17 | StreetInsider |
| May 27, 2026 | Piper Sandler | Kelsey Goodwin | $20.00(+107%) | $9.67 | StreetInsider |
| Feb 18, 2026 | Mizuho Securities | $10.00(+110%) | $4.76 | TheFly | |
| Sep 19, 2025 | Mizuho Securities | Graig Suvannavejh | $4.00(+4%) | $3.83 | TheFly |
| Jun 22, 2022 | Jefferies | Andrew Tsai | $3.00(+5%) | $2.85 | TheFly |
| Apr 21, 2022 | Berenberg Bank | $33.00(+184%) | $11.63 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Mizuho | maintain | Outperform | Aug 19, 2026 |
| Citizens | maintain | Market Outperform | Aug 17, 2026 |
| Citizens | upgrade | Market Perform →Market Outperform | Jul 30, 2026 |
| Mizuho | upgrade | Neutral →Outperform | Feb 19, 2026 |
| JMP Securities | maintain | Outperform | Aug 10, 2023 |
| Mizuho | maintain | Buy | May 14, 2023 |
| BTIG | maintain | Buy | Mar 29, 2023 |
| JMP Securities | maintain | Market Outperform →Outperform | Mar 24, 2023 |
| Mizuho | maintain | Buy | Jul 7, 2022 |
| Jefferies | downgrade | Buy →Hold | Jun 22, 2022 |
| Stifel | downgrade | Buy →Hold | Jun 22, 2022 |
| JMP Securities | downgrade | Market Outperform →Market Perform | Jun 22, 2022 |
| BTIG | maintain | Buy | May 10, 2022 |
| Berenberg | maintain | Buy | Apr 21, 2022 |
| Goldman Sachs | maintain | Neutral | Dec 15, 2021 |
Earnings History
Next report: Mar 25, 2027 · EPS est. $-0.60| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-0.80 | $-1.39 | — | — |
| May 7, 2026 | $-1.73 | $-2.28 | — | — |
| Mar 26, 2026 | $-18.92 | $-1.35 | — | — |
| Nov 6, 2025 | $-1.68 | $-1.06 | — | — |
| Aug 7, 2025 | $-1.80 | $-1.80 | — | — |
| May 9, 2025 | $-2.30 | $-2.00 | — | — |
| Feb 27, 2025 | $-3.90 | $-0.45 | — | — |
| Nov 7, 2024 | $-7.50 | $-0.80 | — | — |
News
Athira Pharma, Inc. (NASDAQ: LONA - Get Free Report) shares traded down 34.9% during mid-day trading on Friday. The company traded as low as $3.12 and last traded at $3.25. Approximately 343,726 shares were traded during mid-day trading, an increase of 553% from the average daily volume of 52,657 shares. The stock had previously closed at
BOTHELL, Wash., Sept. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that Company management will participate in the Cantor Global Healthcare Conference 2026, taking place September 9-11, 2026 in New York, NY.
On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Expected in 2H 2027
BOTHELL, Wash., Aug. 12, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that its lead product candidate, lasofoxifene, will be featured in multiple presentations at Dava Oncology's 4th Summit on Breast Cancer taking place from August 18-22, 2026, in Kona, Hawaii.